Yusuke Nakamura to Administration, Oral
This is a "connection" page, showing publications Yusuke Nakamura has written about Administration, Oral.
Connection Strength
0.216
-
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22; 6(259):259ra145.
Score: 0.112
-
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol. 2003 Jul; 23(1):29-39.
Score: 0.051
-
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J Med Chem. 2015 Feb 26; 58(4):1760-75.
Score: 0.029
-
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
Score: 0.025